CAPMUL® — Where Formulation Begins™
ABITEC’s CAPMUL bioavailability enhancers are medium-chain mono- and di-glycerides and propylene glycol esters. These functional lipid excipients act as solubilizers and emulsifiers in oral, topical, transdermal, and parenteral drug delivery systems.
ABITEC’s CAPMUL bioavailability enhancers are medium-chain mono- and di-glycerides and propylene glycol esters. These functional lipid excipients act as solubilizers and emulsifiers in oral, topical, transdermal, and parenteral drug delivery systems. CAPMUL excipients are recognized as the ideal starting point when formulating BCS Class II (poorly water soluble) and BCS Class IV (poorly permeable) molecules. Lipid based drug delivery systems may be formulated as liquid or semi-solid formulations for oral dosage forms, as well as creams and ointments for topical and transdermal applications.
CAPMUL may be used as a majority component in solubilization/emulsification formulations. CAPMUL based formulations may also be customized with the inclusion of CAPTEX®medium-chain triglycerides and/or ACCONON®nonionic surfactants, added for enhanced bioavailability.
ABITEC manufactures CAPMUL, CAPTEX and ACCONON high-quality lipid excipients for drug delivery applications in accordance with strict cGMP and applicable IPEC (International Pharmaceutical Excipient Council) guidelines in ISO certified facilities. ABITEC’s customer-preferred portfolio of pharmaceutical excipients are monograph compliant, supported by drug master files (DMFs), and have precedence of use.
Contact Details:
ABITEC Corporation
501 W. 1ST Ave.
Columbus, OH 43215 USA
Website:www.abiteccorp.comE-mail:sales@abiteccorp.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
